CFHL Q2 FY26: Consolidated PAT at Rs 1,214 Cr, up 8%; income grows 20%

Revenue Growth 20pctResults View source PDF Explain this filing

CHOLAHLDNG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.1%Reaction day

₹1961.50

prior close

₹1901.30

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.2%-3.8% vs market

Investment Company peers, median of 59sector+0.1%-4.2% vs sector

On the reaction day the stock moved 3.8 pts less than Nifty Smallcap 250 and 4.2 pts less than its Investment Company peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.1

15m

+0.5

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.1-0.2-3.8+0.1-4.2

Next day

-2.1-0.2-1.8-0.4-1.7

-2.0-0.4-1.6+0.1-2.1

-0.6+0.3-0.9+0.4-1.0

+0.0-0.1+0.1+0.0+0.0

+1.2+0.1+1.1+0.0+1.2

-2.2-0.2-2.0-1.1-1.1

15d

-5.8-1.9-3.9-2.4-3.4

-4.2-5.5+1.3-6.1+1.9

-4.2-1.4-2.7-6.3+2.2

-12.8-4.6-8.2-9.3-3.6

UpDownMarket · Nifty Smallcap 250Sector · Investment Company peers, median of 59Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and H1 FY26 results. Consolidated Q2 income rose 17% to Rs 9,589 Cr, PAT up 8% at Rs 1,214 Cr. H1 income grew 20% to Rs 18,972 Cr, PAT at Rs 2,474 Cr (up 8%). CIFCL subsidiary (44.37% stake) posted Q2 PAT of Rs 1,155 Cr (up 20%), AUM up 33% to Rs 2.14 lakh Cr. Insurance arm CMSGICL Q2 PAT fell to Rs 46 Cr from Rs 153 Cr on mark-to-market losses. Board approved reclassifying Yanmar Coromandel from promoter to public.

Likely market impact

Strong 33% AUM growth at CIFCL and 20% income growth support positive outlook, but sharp PAT decline at insurance arm CMSGICL due to market value losses may weigh on near-term sentiment.